Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.carrev.2019.07.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine Learning for the Early Prediction of Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage: Systematic Review and Meta-Analysis.
J Med Internet Res
January 2025
Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Background: Delayed cerebral ischemia (DCI) is a primary contributor to death after subarachnoid hemorrhage (SAH), with significant incidence. Therefore, early determination of the risk of DCI is an urgent need. Machine learning (ML) has received much attention in clinical practice.
View Article and Find Full Text PDFIntravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.
Cochrane Database Syst Rev
January 2025
Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.
Background: Cystic fibrosis is a multisystem disease characterised by the production of thick secretions causing recurrent pulmonary infection, often with unusual bacteria. Intravenous (IV) antibiotics are commonly used in the treatment of acute deteriorations in symptoms (pulmonary exacerbations); however, recently the assumption that exacerbations are due to increases in bacterial burden has been questioned. This is an update of a previously published review.
View Article and Find Full Text PDFLurasidone versus typical antipsychotics for schizophrenia.
Cochrane Database Syst Rev
January 2025
Section of Affective Disorders, Department of Psychiatry, Jagiellonian University Medical College, Krakow, Poland.
Background: Antipsychotic drugs are the mainstay of treatment for schizophrenia. Even though several novel second-generation antipsychotics (i.e.
View Article and Find Full Text PDFEfficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review.
Front Pharmacol
January 2025
Department of Pharmacy, Tianjin First Central Hospital, Tianjin, China.
Background: Obinutuzumab was approved in China in June 2021 used in combination with chemotherapy (followed by obinutuzumab maintenance) for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL). The clinical application of obinutuzumab has recently begun in China, but there is a lack of evidence to determine under which circumstances it should be considered the treatment of choice. A comprehensive assessment is necessary to evaluate the efficacy, safety, and cost-effectiveness of obinutuzumab in adult patients with FL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!